Molbio Diagnostics shares rally 6% after strong debut. What should investors do?

Molbio Diagnostics made a strong debut, beating grey market expectations. Experts remain positive on the company’s molecular diagnostics leadership, expansion strategy and industry prospects, though they advise caution after the sharp initial gains and suggest a Rs 900 stop-loss.